Hepatocellular Cancer

Oncology
4
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 1 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
LenvatinibPhase 1Small Molecule1 trial
Active Trials
NCT06858813Recruiting232Est. Sep 2030
Mereo BioPharma
Mereo BioPharmaUK - London
1 program
1
OMP-54F28 with SorafenibPhase 1Small Molecule1 trial
Active Trials
NCT02069145CompletedEst. Jul 2017
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
SorafenibPhase 1Small Molecule1 trial
Active Trials
NCT00997022Completed14Est. May 2015
Bayer
BayerLEVERKUSEN, Germany
1 program
1
SorafenibPhase 1Small Molecule
Roche
RocheSTAVANGER NORWAY, Norway
1 program
FoundationOne®CDx and FoundationOne®LiquidN/A1 trial
Active Trials
NCT04484636Completed400Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AbbVieLenvatinib
Mereo BioPharmaOMP-54F28 with Sorafenib
AmgenSorafenib
RocheFoundationOne®CDx and FoundationOne®Liquid

Clinical Trials (4)

Total enrollment: 646 patients across 4 trials

NCT06858813AbbVieLenvatinib

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Start: Apr 2025Est. completion: Sep 2030232 patients
Phase 1Recruiting
NCT02069145Mereo BioPharmaOMP-54F28 with Sorafenib

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

Start: Jan 2014Est. completion: Jul 2017
Phase 1Completed
NCT00997022AmgenSorafenib

Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

Start: May 2009Est. completion: May 201514 patients
Phase 1Completed
NCT04484636RocheFoundationOne®CDx and FoundationOne®Liquid

PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Start: Oct 2020Est. completion: Dec 2024400 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3h ago

Office Administrator

SystImmune
3h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 646 patients
Small Molecule is the dominant modality (100% of programs)
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)